Duraxyl 100 mg is an oil-based nandrolone phenylpropionate injectable manufactured by Kalpa Pharmaceuticals and dosed at 100 mg/mL in a 10 mL vial.
Duraxyl 100 mg is an injectable anabolic-androgenic steroid containing nandrolone phenylpropionate (NPP), a short-to-medium acting ester of the nandrolone hormone. Nandrolone is structurally a 19-nortestosterone derivative, meaning it lacks the 19-methyl group found in testosterone. This structural difference gives nandrolone a lower androgenic profile relative to its anabolic activity.
The phenylpropionate ester releases nandrolone more rapidly than the longer decanoate ester used in Nandrolone Decanoate (Deca-Durabolin). This makes NPP a shorter-acting alternative that requires more frequent administration but allows for faster clearance from the body. In non-medical bodybuilding settings, NPP is commonly referenced for its anabolic properties, particularly in contexts where joint comfort and lean mass support are considerations.
Nandrolone promotes muscle protein synthesis through androgen receptor activation. When used at supraphysiologic levels for physique or performance enhancement, the potential for adverse effects also increases and such use falls outside approved medical indications.
Duraxyl 100 mg uses MCT oil as its carrier oil, providing the oil base for the nandrolone phenylpropionate formulation.
Nandrolone phenylpropionate is a short-to-medium acting ester of nandrolone, designed for more rapid release and clearance than longer-acting nandrolone preparations. Its ester chain and 19-nortestosterone structure distinguish it from testosterone and other anabolic compounds.
The phenylpropionate ester releases nandrolone from the injection site more quickly than the decanoate ester used in Nandrolone Decanoate. This gives NPP a shorter half-life (approximately 4–5 days) and a faster clearance profile. Once released, the active hormone is nandrolone, which binds to the androgen receptor and promotes anabolism in skeletal muscle.
Nandrolone differs from testosterone structurally in lacking the 19-methyl group. This modification reduces its conversion to dihydrotestosterone (DHT) in 5-alpha-reductase-rich tissues. Instead, the 5-alpha reduced metabolite of nandrolone has lower androgen receptor binding affinity than nandrolone itself, resulting in a lower androgenic profile.
These characteristics explain why NPP is commonly referenced in non-medical bodybuilding settings where a shorter-acting nandrolone is preferred over the longer decanoate ester, particularly in contexts where faster clearance or more frequent administration is desired.
Nandrolone phenylpropionate releases nandrolone more rapidly than the decanoate ester. Its half-life of approximately 4–5 days is shorter than Nandrolone Decanoate, requiring more frequent injection but allowing faster clearance from the body.
Kalpa Pharmaceuticals offers several nandrolone and nandrolone-related formulations. The main practical distinction is the ester, which determines the release rate and injection frequency.
Duraxyl 100 mg uses the phenylpropionate ester, which is shorter-acting than the decanoate ester in Nandroxyl 250. For a comparable nandrolone preparation with a longer release profile, Nandroxyl 250 provides nandrolone decanoate at 250 mg/mL. For users seeking a testosterone base to stack with a nandrolone, Testoxyl Cypionate 250 or Testoxyl Propionate are commonly referenced options.
The information below is provided for educational reference only. Nandrolone phenylpropionate is a prescription-class androgen in jurisdictions where it remains available; medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring. Non-medical use falls outside approved indications.
In non-medical bodybuilding settings, nandrolone phenylpropionate is commonly referenced in the range of 100–150 mg every other day, or approximately 200–300 mg per week, though such use falls outside approved medical indications. Because of its shorter half-life compared to the decanoate ester, NPP requires more frequent administration to maintain stable blood levels.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Non-medical bodybuilding | 100–150 mg per injection | Every other day |
| Weekly equivalent | 200–300 mg / week | Split into EOD injections |
| Stacking base compound | Typically combined with a testosterone base | Per cycle protocol |
In non-medical bodybuilding contexts, NPP is frequently referenced as a secondary compound stacked alongside a testosterone base. Because nandrolone suppresses endogenous testosterone production, a testosterone base is often included to maintain physiological testosterone levels. Kalpa offers several testosterone preparations that are commonly referenced in this context, including Testoxyl Cypionate 250 and Testoxyl Enanthate 250.
NPP may also be referenced alongside oral compounds such as Dianoxyl 10 for mass-building phases or Stanoxyl 10 during cutting phases. Cycle structure, duration and support compounds should be considered in the context of individual experience, health status and bloodwork where possible.
Nandrolone does not aromatize to a significant degree, so estrogenic side effects such as gynecomastia and water retention are less pronounced than with testosterone. However, nandrolone can be associated with prolactin-related effects in some users. Cabergoline-like compounds are sometimes referenced for prolactin management in non-medical contexts.
Nandrolone is known to suppress endogenous testosterone production and can reduce libido in some users. Cholesterol and hematocrit levels should be monitored during use. Aromatase inhibitors such as Arimixyl are generally less relevant with nandrolone alone but may be referenced when stacking with aromatizable compounds.
After completing a cycle with Duraxyl 100 mg, post-cycle therapy is commonly recommended to help restore endogenous testosterone production and support hormonal recovery. Agents such as Clomixyl or Nolvaxyl are commonly referenced for this purpose.
Because NPP has a shorter half-life than nandrolone decanoate, some users reference a shorter waiting period between the last injection and the start of PCT. PCT protocols vary based on cycle length, compounds used and individual factors.
Dosing strategies, support compounds and recovery protocols should be adjusted based on experience level and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Nandrolone phenylpropionate is an androgen that can affect hormonal, reproductive, cardiovascular and hematologic function. Medical use requires appropriate diagnosis, clinical supervision and ongoing monitoring.
Nandrolone phenylpropionate is not currently marketed as an FDA-approved human pharmaceutical product in the United States. The original Durabolin product is discontinued. Its safety and efficacy have not been established through the clinical trial process required for current FDA human pharmaceutical approval.
Use of nandrolone phenylpropionate at supraphysiologic levels for bodybuilding or performance enhancement falls outside any approved indication and can increase exposure to androgen-related adverse effects.
Higher-than-physiologic nandrolone exposure can carry additional health risks. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
Nandrolone can suppress endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal axis. This can lead to reduced testicular function, impaired fertility, and reduced libido in some users.
Nandrolone is associated with prolactin-related effects in some users, which may manifest as changes in sexual function or mood. Cardiovascular markers including lipid profile and blood pressure should be monitored during use.
Other potential androgen-related effects can include acne and changes in skin oil production. Individual response and risk vary according to health status, exposure and other factors.
Anabolic steroid use is not appropriate for everyone. Medical guidelines identify circumstances in which androgen therapy should be avoided or carefully evaluated, including known or suspected prostate or male breast cancer, elevated hematocrit, certain cardiovascular conditions, thrombophilia and near-term fertility plans.
Existing cardiovascular disease, abnormal blood counts and other medical conditions should be discussed with a qualified healthcare professional before any androgen use is considered.
Medically supervised androgen therapy typically involves follow-up assessment to evaluate treatment response, adverse effects and relevant laboratory markers. Monitoring may include testosterone concentrations, hematocrit, lipid profile, and prolactin where relevant.
For non-medical use of Duraxyl 100 mg, such monitoring is not typically performed, which increases the risk of unrecognized adverse effects.
Keep the vial securely stored and protected from conditions that could compromise the product or container. Inspect the vial and solution before use and do not use a product that appears damaged, contaminated or otherwise abnormal.
Keep all medications and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Duraxyl 100 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
To verify your Duraxyl 100 mg product, use the security code on the vial label and cross-check it on the Kalpa official site. Official Kalpa Pharmaceuticals presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at controlled room temperature (15–25°C) and protect from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the oily formulation.
Keep the vial in its original packaging until use. Do not freeze. Before administration, inspect the solution and avoid use if it appears cloudy, discolored, contains particulate matter, or if the vial or seal is compromised.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Duraxyl 100 mg, nandrolone phenylpropionate, release characteristics, product strength and how it compares to other nandrolone preparations.
NPP stands for Nandrolone Phenylpropionate. It is a short-to-medium acting ester of the anabolic steroid nandrolone, distinguished from the longer-acting Nandrolone Decanoate (commonly known as Deca) by its faster release and clearance profile.
Duraxyl 100 mg contains nandrolone phenylpropionate. In non-medical bodybuilding settings it is commonly referenced as a secondary compound for lean mass and joint comfort support, though such use falls outside approved medical indications.
Because of its shorter half-life compared to nandrolone decanoate, nandrolone phenylpropionate is typically referenced as being administered every other day. This frequency is necessary to maintain stable blood levels with the phenylpropionate ester.
Nandrolone phenylpropionate is a prodrug of nandrolone. Once released, nandrolone binds to the androgen receptor and promotes anabolism in skeletal muscle. Nandrolone has a favorable anabolic-to-androgenic ratio compared to testosterone, meaning it has strong muscle-building effects with a lower androgenic profile.
Nandrolone phenylpropionate is a short-to-medium acting ester, so circulating nandrolone rises relatively quickly after administration compared to longer-ester preparations. Its effects are correspondingly shorter-lived between injections.
The time required to notice a change depends on what is being evaluated, the individual's starting hormone levels, treatment circumstances and other biological factors.
NPP and Deca both contain the same active hormone (nandrolone) but use different esters. NPP uses the phenylpropionate ester, which releases nandrolone more rapidly and has a shorter half-life. Deca uses the decanoate ester, which releases nandrolone more slowly and requires less frequent injection. Kalpa offers Nandroxyl 250 as the longer-acting decanoate formulation.
There is no single nandrolone ester that is universally best. NPP and nandrolone decanoate differ primarily in their release rates and injection frequencies. The appropriate choice depends on the circumstances in which nandrolone is being used.
A milligram amount cannot be classified as appropriate or excessive without considering the medical indication, individual response, laboratory results, treatment schedule and the specific product being used. In non-medical contexts, nandrolone phenylpropionate is commonly referenced in the 100–150 mg per injection range.
It is also important to distinguish a dose in milligrams from a product's concentration in mg/mL. Duraxyl 100 mg is labeled at 100 mg/mL; that concentration does not by itself specify how much should be administered.
Duraxyl 100 mg is labeled at 100 mg of nandrolone phenylpropionate per mL. It is supplied in a 10 mL vial, giving 1,000 mg of total labeled nandrolone phenylpropionate content per vial.
Nandrolone is not typically associated with anxiety to the same degree as some other compounds. However, individual psychological responses to anabolic steroids vary, and some users report mood changes. Any psychological effects should be discussed with a qualified healthcare professional.
Nandrolone phenylpropionate is typically formulated at lower concentrations because the phenylpropionate ester is a shorter-chain ester that can be more difficult to keep in stable solution at higher concentrations. The 100 mg/mL concentration is a practical formulation choice for this ester.